Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue International Journal of Pharmaceutics Année : 2023

Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody

François Noverraz
  • Fonction : Auteur
Bénédicte Fauvel
  • Fonction : Auteur
Alan Cookson
  • Fonction : Auteur


COVID-19 is caused by the infection of the lungs by SARS-CoV-2. Monoclonal antibodies, such as sotrovimab, showed great efficiency in neutralizing the virus before its internalization by lung epithelial cells. However, parenteral routes are still the preferred route of administration, even for local infections, which requires injection of high doses of antibody to reach efficacious concentrations in the lungs. Lung administration of antibodies would be more relevant requiring lower doses, thus reducing the costs and the side effects. But aerosolization of therapeutic proteins is very challenging, as the different processes available are harsh and trigger protein aggregation and conformational changes. This decreases the efficiency of the treatment, and can increase its immunogenicity. To address those issues, we developed a series of new excipients composed of a trehalose core, a succinyl side chain and a hydrophobic carbon chain (from 8 to 16 carbons). Succinylation increased the solubility of the excipients, allowing their use at relevant concentrations for protein stabilization. In particular, the excipient with 16 carbons (C16TreSuc) used at 5.6 mM was able to preserve colloidal stability and antigen-binding ability of sotrovimab during the nebulization process. It could also be used as a cryoprotectant, allowing storage of sotrovimab in a lyophilized form during weeks. Finally, we demonstrated that C16TreSuc could be used as an excipient to stabilize antibodies for the treatment against COVID-19, by in vitro and in vivo assays. The presence of C16TreSuc during nebulization preserved the neutralization capacity of sotrovimab against SARS-CoV-2 in vitro; an increase of its efficacy was even observed, compared to the non-nebulized control. The in vivo study also showed the wide distribution of sotrovimab in mice lungs, after nebulization with 5.6 mM of excipient. This work brings a solution to stabilize therapeutic proteins during storage and nebulization, making pulmonary immunotherapy possible in the treatment of COVID-19 and other lung diseases


Fichier principal
Vignette du fichier
1-s2.0-S0378517322010183-main.pdf (3.13 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03935985 , version 1 (23-03-2023)




François Noverraz, Baptiste Robin, Solène Passemard, Bénédicte Fauvel, Jessy Presumey, et al.. Novel trehalose-based excipients for stabilizing nebulized anti-SARS-CoV-2 antibody. International Journal of Pharmaceutics, 2023, 630, pp.122463. ⟨10.1016/j.ijpharm.2022.122463⟩. ⟨hal-03935985⟩
42 Consultations
45 Téléchargements



Gmail Mastodon Facebook X LinkedIn More